A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.
Alzheimer's Research UK, Cambridge; Reta Lila Weston Laboratories, London; Department of Molecular Neuroscience, University College London, London, United Kingdom.
Eric
E
Karran
John
J
Hardy
D000544:Alzheimer Disease / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic / Q000592:standards*; D055808:Drug Discovery / Q000592:standards*; D006801:Humans; D058225:Plaque, Amyloid / Q000188:drug therapy*